

**ASX ANNOUNCEMENT**

20 September 2024

## Appointment of Executive Director to Clarity's Board

**Clarity Pharmaceuticals** (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to confirm the appointment of Ms Michelle Parker to its Board effective 20 September 2024, in line with the announcement dated 26 August 2024, having now completed all formal requirements.

**Clarity's Executive Chairperson, Dr Alan Taylor, commented,** "We are very pleased to be welcoming Michelle to the Board and look forward to continuing working together on advancing our clinical development program. Given her significant contributions to Clarity's clinical program success to date and invaluable input as a Senior Executive Team member, Michelle's extensive experience and expertise will be highly appreciated at the Board level."

**Ms Parker commented on her appointment to the Board,** "I am excited to continue contributing to growing Clarity and its pipeline of best-in-class products now in the role of Executive Director as well as Chief Clinical Officer. With excellent data generated to date in our clinical programs, and the radiopharmaceutical sector gaining momentum, we look forward to providing patients with access to potentially life-changing radiopharmaceuticals."

### About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

[www.claritypharmaceuticals.com](http://www.claritypharmaceuticals.com)

### For more information, please contact:

Clarity Pharmaceuticals  
Dr Alan Taylor  
Executive Chairperson  
[ataylor@claritypharm.com](mailto:ataylor@claritypharm.com)

Catherine Strong  
Investor/Media Relations  
[catherine.strong@sodali.com](mailto:catherine.strong@sodali.com)  
+61 406 759 268

*This announcement has been authorised for release by the Executive Chairperson.*